Patent · US Active

Antibody formulations

US10316095B2 · kind B2 · utility

6Cited by
44References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 14, 2013
Grant dateJun 11, 2019
Priority date—
Expiry dateMar 25, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Formulations of anti-VLA-1 antibodies are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.